Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience (NASDAQ:HBIO) sees FY2026 sales of $89.147 million-$90.877 million vs $88.600 mil

Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analy

HOLLISTON, Mass. , July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will an

On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company"

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analy

First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operati

HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today ann

HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will an

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative

Harvard Bioscience (NASDAQ: HBIO) executives highlighted a year of "foundation building" and cost an

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Harvard Bioscience (NASDAQ:HBIO) sees Q1 sales of $20.000 million-$22.000 million vs $21.250 million

Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $23.735 million which beat the analyst

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M a

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on Mar

Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report)'s stock price passed above its two hundred

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today a

HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will ann

Shares of Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report) crossed below its 200-day moving

Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a g

Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidan

Harvard Bioscience restructures production, closing MA plant, shifting output to US and abroad. Savi

Streamlining production footprint and improving manufacturing efficiency through phased closure of H

Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), tod

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flex

Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report) shares crossed above its two hundred day m

Former Treasury Secretary Larry Summers said he was stepping back from all public commitments amid f

Harvard Bioscience (NASDAQ:HBIO) sees Q4 sales of $22.500 million-$24.500 million vs $23.100 million

Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $20.591 million which beat the analyst

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative